WuXi ups its revenue ambitions after M&A and expansion

WuXi PharmaTech CEO Ge Li

Chinese CRO WuXi PharmaTech ($WX) is forecasting a better-than-expected 2014 after a strong third quarter and some timely deals, moving into the new year with hopes for continued global growth.

WuXi's quarterly revenue jumped 18% to $173.6 million in Q3, a gain driven by 16% growth in its lab services business and a 23% leap in manufacturing. Net income came in at $32 million on the quarter, a 5% increase over last year.

Now WuXi is slightly increasing its full-year projections, accounting for its September buyout of CRO XenoBiotic Laboratories and its guidance-exceeding third-quarter performance. The company expects to pull in as much as $672 million in 2014, an improvement over its previously announced range of between $665 million and $670 million.

"We continue to believe that our future is bright," WuXi CEO Ge Li said in a statement. "We expect particularly strong growth in small-molecule manufacturing and biologics for the next several years, as we capitalize on the growing late-stage and commercial product pipeline in small-molecule manufacturing and the ramp-up of our biologics manufacturing business."

WuXi, China's largest CRO, has been steadily growing its share of the global R&D market thanks to escalating demand for its discovery services and a broad-based expansion of its manufacturing platform. The company has also invested heavily in genomics, constructing China's first CLIA-certified lab in Shanghai and partnering with the likes of Illumina ($ILMN), Foundation Medicine ($FMI) and Pacific Biomarkers to flesh out its offerings in the field.

- read the results

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

Aetion has raised $50 million so far, and it plans to enhance its platform to support more complex therapeutic areas and expand its team.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.